Suppliers and packagers for INVEGA TRINZA

INVEGA TRINZA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Janssen Pharms	INVEGA TRINZA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946	NDA	Janssen Pharmaceuticals, Inc	50458-606-01	1 SYRINGE in 1 KIT (50458-606-01) / 1 mL in 1 SYRINGE	2015-05-19
Janssen Pharms	INVEGA TRINZA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946	NDA	Janssen Pharmaceuticals, Inc	50458-607-01	1 SYRINGE in 1 KIT (50458-607-01) / 1 mL in 1 SYRINGE	2015-05-19
Janssen Pharms	INVEGA TRINZA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946	NDA	Janssen Pharmaceuticals, Inc	50458-608-01	1 SYRINGE in 1 KIT (50458-608-01) / 1 mL in 1 SYRINGE	2015-05-19
Janssen Pharms	INVEGA TRINZA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946	NDA	Janssen Pharmaceuticals, Inc	50458-609-01	1 SYRINGE in 1 KIT (50458-609-01) / 1 mL in 1 SYRINGE	2015-05-19

Suppliers and packagers for INVEGA TRINZA

Last updated: May 27, 2026

Invega Trinza (paliperidone palmitate) Suppliers: Who Manufactures, Fills, and Supplies the Franchise Globally?

Executive summary: Invega Trinza is an injectable, long-acting antipsychotic in the paliperidone palmitate franchise. At launch and through subsequent lifecycle updates, production and supply are centered on Janssen’s manufacturing network and its contracted fill-finish partners. In the US market, the product is marketed by Janssen Biotech, Inc. and supplied through Janssen’s commercial supply chain and related contract manufacturers listed in FDA submissions and labeling.

Net:

• Brand owner/market authorization holder: Janssen Biotech, Inc.
• Product type: Extended-release injectable suspension (paliperidone palmitate), 3-month dosing interval
• Manufacturing and supply structure: Janssen-developed drug substance and long-acting injectable drug product supply, with contract manufacturing and sterile fill-finish capacity used for batch production.

Who supplies Invega Trinza in the US and which companies fill-finish it?

Answer (US): Invega Trinza is marketed by Janssen Biotech, Inc. under the Janssen commercial supply chain. The actual commercial manufacturing locations and fill-finish suppliers for each marketed strength are defined in FDA product documentation tied to the New Drug Application and current labeling.

US label “supplied by” vs. manufacturing site lists

• US prescribers see “Manufactured for Janssen…” style statements in packaging and labeling.
• The underlying manufacturing network (API/drug substance sites, sterile drug product, lyophilized/intermediate steps if any, and vial/syringe fill-finish) is reflected in FDA Chemistry Manufacturing and Controls (CMC) content and in establishment listings supporting FDA inspections and lot release.

How to map “suppliers” for Invega Trinza

For procurement, licensing, and litigation readiness, “suppliers” typically split into:

1. Marketing authorization holder (responsible party on US label)
2. Drug substance manufacturer (paliperidone palmitate API/drug substance supply)
3. Sterile fill-finish / drug product manufacturer (suspension preparation, sterile manufacturing controls, packaging)
4. Global logistics partners (temperature-controlled distribution, returns and warehousing)
5. Specialty logistics for depot injectables (handling that preserves suspension integrity)

What companies manufacture paliperidone palmitate for Invega Trinza?

Answer: Paliperidone palmitate for Invega Trinza is produced within Janssen’s long-acting depot injectable manufacturing ecosystem. The specific drug substance and drug product manufacturing site names vary by region, batch, and revision of CMC packages, and are documented in FDA submissions and labeling updates.

Supply chain pattern across the paliperidone palmitate depot line

Invega Trinza sits in the same family as:

• Invega Sustenna (1-month)
• Invega Hafyera (6-month)

This franchise typically shares:

• Drug substance platform chemistry
• Long-acting formulation development
• Sterile injectable manufacturing and fill-finish know-how

Procurement due diligence commonly confirms:

• Whether drug substance is centralized or multiple-site
• Whether fill-finish is single-site for depot injectables or regionally redundant
• Whether suspension preparation uses the same intermediate handling systems across SKUs

Which contract manufacturing organizations (CMOs) produce Invega Trinza drug product?

Answer: The drug product is produced under Janssen’s oversight with industrial partners that handle sterile manufacturing and depot injectable fill-finish. The identities are embedded in FDA CMC documentation and inspection establishment lists, and typically include one or more specialized sterile manufacturing facilities aligned to long-acting injectable requirements.

What “C denotes CMO risk” looks like in depot injectables

For business planning, contract manufacture matters because:

• Sterile manufacturing and particulate control have higher qualification barriers
• Suspension homogeneity and depot-specific viscosity targets require process lock
• Batch release testing capacity and stability programs constrain surge supply

What is the FDA regulatory status of Invega Trinza and what does it imply for suppliers?

Answer: Invega Trinza is a marketed, FDA-approved antipsychotic injectable. Supplier identification for CMC and inspection planning is tied to the NDA and its manufacturing supplements, which define:

• Established manufacturing sites
• Drug substance and drug product responsibilities
• Sterility assurance and aseptic processing controls
• Release testing responsibilities

Orange Book / FDA listings: what suppliers can be confirmed from

Even where product labeling names the “for Janssen” manufacturer, the FDA ecosystem includes:

• Drug establishment inspection assignments
• Manufacturing site identifiers used by FDA investigators
• CMC structure for post-approval manufacturing changes

For supplier mapping in litigation and regulatory submissions, these manufacturing identifiers and site responsibilities are the actionable dataset.

How many suppliers are in the Invega Trinza estate by site type (drug substance vs drug product)?

Answer: The franchise is typically multi-tier. The practical supplier count is usually:

• One or more drug substance sites
• One or more sterile drug product fill-finish sites
• Single marketing authorization holder in the US

A supplier “count” cannot be stated precisely from public-facing label language alone because CMC revisions can add or remove sites over time. The complete site list is defined by FDA-reviewed manufacturing changes across NDA supplements.

How does Invega Trinza supply compare with Invega Sustenna (1-month) and Invega Hafyera (6-month)?

Answer: All three are paliperidone palmitate depot injectables. Supply chain structure follows a shared platform approach:

• Similar API family and formulation platform
• Different depot interval-specific formulation and drug product specs
• Different packaging presentations and injection devices

What changes across the line is:

• The exact depot interval-specific formulation batch records
• The sterile fill-finish configurations and needle device integration
• Regional allocations based on inspection readiness and capacity

What suppliers are used for distribution and cold-chain handling of Invega Trinza?

Answer: Distribution is managed within Janssen’s US and global supply chain using specialized logistics partners capable of handling injectable specialty products. Cold-chain requirements and deviation handling procedures are defined in product distribution SOPs and shipper qualification programs.

For depot injectables, the actionable supplier considerations are:

• Temperature excursions handling
• Return and destruction channels
• Control of sample and batch traceability during transfer

What patent or exclusivity events affect supplier risk for Invega Trinza?

Answer: Supplier risk is driven more by product exclusivity and manufacturing constraints than by site identity. Patent estates and exclusivity windows affect:

• The ability of would-be manufacturers to commercialize generic versions
• The likelihood of supply continuity via commercial agreements or settlements
• The timeline for biosimilar-like alternatives (paliperidone palmitate is a small-molecule depot, not a biologic)

For procurement planning, the key risk categories are:

• Patent enforcement impacting availability of cost-reduced alternatives
• Settlement agreements that may restrict competition
• Manufacturing change approvals that shift supply site allocations

Key Takeaways

• Invega Trinza’s US market authorization is held by Janssen Biotech, Inc., and supply is executed through Janssen’s manufacturing network and contract sterile fill-finish partners under Janssen oversight.
• The actionable supplier list (site-level drug substance and sterile drug product roles) is determined by FDA-reviewed CMC/manufacturing site designations rather than label-only “manufactured for” language.
• The paliperidone palmitate depot franchise has shared platform manufacturing capabilities across monthly and longer-interval products, while interval-specific formulation and packaging systems drive differences in fill-finish qualification and capacity.

FAQs

1. Who is the marketing authorization holder for Invega Trinza in the US?
2. What manufacturing sites define the drug substance and sterile drug product responsibilities for Invega Trinza?
3. Are the suppliers for Invega Trinza the same as for Invega Sustenna and Invega Hafyera?
4. What procurement diligence is most important for sterile depot injectable CMOs producing Invega Trinza?
5. How do patent and exclusivity milestones affect the competitive supply risk around Invega Trinza?

References (APA)

1. FDA. (n.d.). Drug approvals and labeling resources for Invega Trinza (paliperidone palmitate). U.S. Food and Drug Administration.
2. DailyMed. (n.d.). Invega Trinza prescribing information and label details. U.S. National Library of Medicine.